Press release
Explore New Strategies to Maintain a Global Pharmacovigilance System this June at SMi’s 5th Drug Safety conference
SMi's 5th Drug Safety conference will take place on the 11th - June 2018, in London, UK. Hear from Astellas, Mundipharma Research and Lygature as they will be exploring the 'Improvements on Signal Detection', on day 2.Benefit from Astellas, Mundipharma Research and Lygature on Day 2 to explore Eudravigilance in Practice
Bert P. van Leeuwen, Deputy Qualified Person for Pharmacovigilance, Astellas will be examining: 'Signal Detection and Management 2018 in the EU: First experiences with Eudravigilance.'
Summary of presentation:
- Informing the EMA and national competent authorities of validated signals
- A review of our experiences so far
- Developing and finalising a process for Eudravigilance
Heike Benecke, Director of Vigilance Risk Management, Mundipharma Research will be exploring: 'ICSR Download from Eudravigilance in practice: First Experiences and Hurdles with Generic Products.'
Summary of presentation:
- Hurdles in the management of E2BR3 cases in E2BR2 environment
- First experiences using Eudravigilance download functionalities
- Management of Eudravigilance cases in global environment
- Effect of Eudravigilance cases in safety data base on MAH signalling activities and processes: effects of “conservative” case download
Kevin Klein, Project Manager, Lygature will be discussing: 'Is more always better? Non-value added reports from patient support programmes as an example of the ‘precautionary reporting bias'.’
Summary of presentation:
- A large number of nonvalue-added reports have been accumulating in ADR databases that can potentially impede safety signal detection
- The extensive patient contact by MAHs in such patient support programs was identified as an important source of such nonvalue-added reports
- These reports could be regarded as precautionary reports by MAHs to meet regulatory requirement
- In this presentation, they demonstrate the suppressing effect of such precautionary reports on statistical signal detection methods
Download the complete brochure online for all sessions and speaker line-up: www.drugsafetyconference.co.uk/pr
For those looking to attend there are currently early-bird rates available up to £400, for a limited time only!
Further information is available at: www.drugsafetyconference.co.uk/opr
SMi presents the 5th conference on:
Drug Safety 2018
Date: 11th – 12th June 2018
Workshops: 13th June 2018
Location: Holiday Inn Kensington Forum, London UK
Website: www.drugsafetyconference.co.uk/opr
---end---
Contact Information:
For all media inquiries contact Pav Solanki on Tel: +44 (0)20 7827 6048 / Email: psolanki@smi-online.co.uk
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Westminster Bridge Road
1
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Explore New Strategies to Maintain a Global Pharmacovigilance System this June at SMi’s 5th Drug Safety conference here
News-ID: 985983 • Views: …
More Releases from SMi Group

Exclusive Speaker Interview with AOBiome ahead of the 22nd Pain Therapeutics Con …
SMi Reports: Exclusive speaker interview with Todd Krueger at AOBiome released for the Pain Therapeutics Conference
The pain therapeutics industry has grown at an exponential rate in recent years. The 22nd Annual Pain Therapeutics conference will cover the leading advances in pain therapeutics, exploring late development clinical trials, novel treatments for chronic conditions, technology collaboration treatments, using VR and Medical Devices that carry out non-invasive nerve stimulation.
Industry leaders will uncover the…

Exclusive Speaker Interview with Ester Lovsin Barle ahead of the 6th Annual High …
Now in its 6th year, the Highly Potent Active Pharmaceutical Ingredients conference offers you peer-to-peer networking with industry experts including heads and directors of EHS, Occupational Hygiene, Quality Assurance and more. Taking place on 9th and 10th May in London, UK.
With a key focus on expanding your community and exploring the latest developments in the industry at this two-day event, including key regulatory updates, and leading case studies from leading…

FDA Keynote Speaker at SMi's 5th Annual Pharmaceutical Microbiology East Coast C …
SMi Group Reports: Keynote FDA speaker Dr. John Arigo, to present at the 4th Annual Pharmaceutical Microbiology East Coast, taking place in just 3 weeks' time on April 27th and 28th, 2022.
With just three weeks remaining until the highly anticipated conference, SMi Group are delighted to announce a key FDA Speaker joining the 5th Annual Pharmaceutical Microbiology East Coast Conference. This event will take place on April 27th and…
Group Captain (ret'd) Robert Daisley invites you to attend Air Mission Planning …
SMi Group reports: Chairman Group Captain (ret'd) Robert Daisley of the Air Mission Planning and Support Conference cordially invites experts to join the conference in London, UK in one week.
With only one week remaining, SMi Group is delighted to publish an invitation letter for SMi's 13th Annual Air Mission Planning & Support Conference, taking place on the 6th and 7th April 2022 in London, UK from the conference chairman.
The…
More Releases for Eudravigilance
Pharmacovigilance World 2025 Conference & Expo
We are delighted to welcome you to the Pharmacovigilance World 2025, and we are confident that your active participation will contribute to the advancement of drug safety practices. Together, let us strive towards a safer and more vigilant healthcare system that prioritizes patient well-being and ensures the continued benefit of medications worldwide.
As medical science advances, so does our understanding of drug safety and the need for vigilance when it comes…
Pharmacovigilance and Drug Safety Software Market Size, Share and Industry Analy …
Pharmacovigilance and Drug Safety Software Industry
Summary:
● The global pharmacovigilance and drug safety software market size reached USD 202.3 Million in 2023.
● The market is expected to reach USD 341.5 Million by 2032, exhibiting a growth rate (CAGR) of 5.9% during 2024-2032.
● North America leads the market, accounting for the largest pharmacovigilance and drug safety software market share.
● Adverse event reporting software accounts for the majority of the market share in the functionality segment…